Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Therapeutic IDOL Reduction Ameliorates Amyloidosis and Improves Cognitive Function in APP/PS1 Mice.

Authors: Gao, Jie; Littman, Russell; Diamante, Graciel; Xiao, Xu; Ahn, In Sook; Yang, Xia; Cole, Tracy A; Tontonoz, Peter

Published In Mol Cell Biol, (2020 03 30)

Abstract: Brain lipoprotein receptors have been shown to regulate the metabolism of ApoE and β-amyloid (Aβ) and are potential therapeutic targets for Alzheimer's disease (AD). Previously, we identified E3 ubiquitin ligase IDOL as a negative regulator of brain lipoprotein receptors. Genetic ablation of Idol increases low-density lipoprotein receptor protein levels, which facilitates Aβ uptake and clearance by microglia. In this study, we utilized an antisense oligonucleotide (ASO) to reduce IDOL expression therapeutically in the brains of APP/PS1 male mice. ASO treatment led to decreased Aβ pathology and improved spatial learning and memory. Single-cell transcriptomic analysis of hippocampus revealed that IDOL inhibition upregulated lysosomal/phagocytic genes in microglia. Furthermore, clustering of microglia revealed that IDOL-ASO treatment shifted the composition of the microglia population by increasing the prevalence of disease-associated microglia. Our results suggest that reducing IDOL expression in the adult brain promotes the phagocytic clearance of Aβ and ameliorates Aβ-dependent pathology. Pharmacological inhibition of IDOL activity in the brain may represent a therapeutic strategy for the treatment of AD.

PubMed ID: 31964754 Exiting the NIEHS site

MeSH Terms: Alzheimer Disease/metabolism; Alzheimer Disease/physiopathology; Amyloid beta-Peptides/metabolism; Amyloid beta-Protein Precursor/metabolism; Amyloidosis/metabolism*; Amyloidosis/pathology; Animals; Apolipoproteins E/metabolism; Brain/metabolism; Cognition/physiology; Disease Models, Animal; Hippocampus/metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia/metabolism; Microglia/pathology; Oligodeoxyribonucleotides, Antisense/pharmacology; Receptors, LDL/metabolism; Ubiquitin-Protein Ligases/genetics*; Ubiquitin-Protein Ligases/metabolism*

Back
to Top